The Role of Ocimene in Decreasing α-Synuclein Aggregation using Rotenone-induced Rat Model
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
BACKGROUND: Parkinson's disease is defined by the loss of dopaminergic neurons in the midbrain of substantia nigra associated with Lewy bodies. The precise mechanism is not yet entirely understood.
OBJECTIVE: The study aims to determine whether ocimene has antiparkinsonian activity by reducing α-Synuclein aggregation levels in the brains of rotenone-induced rat models.
METHODS: 36 male rats were used for six groups, with six animals in each group. Vehicle, control (rotenone, 2.5 mg/kg, i.p), standard (L-Dopa, 10 mg/kg, i.p), Test drug of low dose (66.66 mg/kg, i.p), medium dose (100 mg/kg, i.p), and high dose (200 mg/kg, i.p) were administered to the rats. The open field, actophotometer, hanging wire, and catalepsy tests were used to assess the rat's motor performance. The expressions of biomarkers such as AchE, D2 Receptor, and α- Synuclein were evaluated, and their level of expression in the brain samples was checked using ELISA. Histopathological analysis was also carried out to determine the degree of neuron degeneration in the brain samples.
RESULTS: The open field test showed significant anxiety levels, whereas test groups showed fewer anxiety levels but increased motor activity. The biochemical tests revealed that rotenonetreated rats had higher levels of AchE, but ocimene-treated rats had a significant decrease in AchE levels. The test drug-treated rats also expressed high levels of D2 receptors. In ocimenetreated rats, α-Synuclein aggregation was reduced, however, in rotenone-treated rats' brain samples, higher clumps of α-Synuclein were observed.
CONCLUSION: Ocimene has neuroprotective properties. As a result, this essential oil might be helpful as a therapeutic treatment for Parkinson's disease.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
---|---|
Enthalten in: |
Central nervous system agents in medicinal chemistry - (2024) vom: 23. Feb. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
S, Ankul Singh [VerfasserIn] |
---|
Links: |
---|
Themen: |
AchE |
---|
Anmerkungen: |
Date Revised 27.02.2024 published: Print-Electronic Citation Status Publisher |
---|
doi: |
10.2174/0118715249283425240212111523 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM368996905 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM368996905 | ||
003 | DE-627 | ||
005 | 20240229165335.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240229s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.2174/0118715249283425240212111523 |2 doi | |
028 | 5 | 2 | |a pubmed24n1309.xml |
035 | |a (DE-627)NLM368996905 | ||
035 | |a (NLM)38409725 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a S, Ankul Singh |e verfasserin |4 aut | |
245 | 1 | 4 | |a The Role of Ocimene in Decreasing α-Synuclein Aggregation using Rotenone-induced Rat Model |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 27.02.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status Publisher | ||
520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
520 | |a BACKGROUND: Parkinson's disease is defined by the loss of dopaminergic neurons in the midbrain of substantia nigra associated with Lewy bodies. The precise mechanism is not yet entirely understood | ||
520 | |a OBJECTIVE: The study aims to determine whether ocimene has antiparkinsonian activity by reducing α-Synuclein aggregation levels in the brains of rotenone-induced rat models | ||
520 | |a METHODS: 36 male rats were used for six groups, with six animals in each group. Vehicle, control (rotenone, 2.5 mg/kg, i.p), standard (L-Dopa, 10 mg/kg, i.p), Test drug of low dose (66.66 mg/kg, i.p), medium dose (100 mg/kg, i.p), and high dose (200 mg/kg, i.p) were administered to the rats. The open field, actophotometer, hanging wire, and catalepsy tests were used to assess the rat's motor performance. The expressions of biomarkers such as AchE, D2 Receptor, and α- Synuclein were evaluated, and their level of expression in the brain samples was checked using ELISA. Histopathological analysis was also carried out to determine the degree of neuron degeneration in the brain samples | ||
520 | |a RESULTS: The open field test showed significant anxiety levels, whereas test groups showed fewer anxiety levels but increased motor activity. The biochemical tests revealed that rotenonetreated rats had higher levels of AchE, but ocimene-treated rats had a significant decrease in AchE levels. The test drug-treated rats also expressed high levels of D2 receptors. In ocimenetreated rats, α-Synuclein aggregation was reduced, however, in rotenone-treated rats' brain samples, higher clumps of α-Synuclein were observed | ||
520 | |a CONCLUSION: Ocimene has neuroprotective properties. As a result, this essential oil might be helpful as a therapeutic treatment for Parkinson's disease | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a AchE | |
650 | 4 | |a Alpha-synuclein | |
650 | 4 | |a D2 receptor | |
650 | 4 | |a L-Dopa | |
650 | 4 | |a Ocimene | |
650 | 4 | |a Rotenone | |
700 | 1 | |a Sood, Aarita |e verfasserin |4 aut | |
700 | 1 | |a Vellapandian, Chitra |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Central nervous system agents in medicinal chemistry |d 2008 |g (2024) vom: 23. Feb. |w (DE-627)NLM185149960 |x 1875-6166 |7 nnns |
773 | 1 | 8 | |g year:2024 |g day:23 |g month:02 |
856 | 4 | 0 | |u http://dx.doi.org/10.2174/0118715249283425240212111523 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |j 2024 |b 23 |c 02 |